Similar observations have been made in ALK+ lung adenocarcinoma: Also here, the main resistance mechanisms to next-line lorlatinib are compound ALK mutations, which affect ∼30% of patients (Shiba-Ishii et al. 2022) and are facilitated by previous treatment with second-generation drugs (Yoda et al. 2018). The gene discussed is ALK; the disease is lung adenocarcinoma.